How chemical restraint
is regulated.
Three documents do most of the work when a Behaviour Support Practitioner is considering whether a psychotropic prescription counts as a regulated restrictive practice: the NDIS Commission's operational framework, the National Disability Insurance Scheme Act 2013 that empowers it, and the ACSQHC clinical-quality standard that sits alongside it. Every substance page on this site links here rather than restating these paragraphs in full.
NDIS Quality and Safeguards Commission
The Commission is the Commonwealth regulator for NDIS-registered providers. Its Regulated Restrictive Practices framework defines the five categories of restrictive practice that require authorisation and reporting — chemical, mechanical, environmental, physical, and seclusion — and sets the operational obligations on providers and Behaviour Support Practitioners.
Chemical restraint specifically means the use of medication or a chemical substance for the primary purpose of influencing a person's behaviour, rather than for the treatment of a diagnosed mental or physical illness. That definition — and the authorisation pathway that follows from it — is the spine of every jurisdictional overlay further down a substance page.
National Disability Insurance Scheme Act 2013
The parent statute. The Act establishes the NDIS Quality and Safeguards Commission, defines the Commissioner's functions, and provides the legislative basis for the rules that operationalise the regulated-restrictive-practices framework — including the NDIS (Restrictive Practices and Behaviour Support) Rules 2018.
For practitioners, the Act is rarely the working document; the Rules and Commission guidance are. It's cited here as the statutory anchor — the source of authority that the operational framework above is exercised under.
ACSQHC Psychotropic Medicines Clinical Care Standard
The Australian Commission on Safety and Quality in Health Care publishes the Psychotropic Medicines in Cognitive Disability or Impairment Clinical Care Standard (2024). Eight quality statements set the clinical bar for psychotropic prescribing in people with cognitive disability: comprehensive assessment, trial of non-pharmacological strategies first, informed consent, monitoring, and time-limited prescribing.
The Standard is not legislation. It carries weight through clinical governance and accreditation pathways, and complements — rather than overlaps with — the NDIS Commission's authorisation framework. A prescription can be clinically appropriate under this Standard and still trigger regulated-restrictive-practice obligations under the NDIS Rules.
What the Behaviour Support Practitioner is doing here
Read the perspective that fits why you're here.
The classification question
A Behaviour Support Practitioner works inside a multi-voice environment by structural necessity. The general practitioner or psychiatrist will frame a medication around a clinical indication. A family member will frame it through lived experience. A support worker will frame it operationally. An occupational therapist, speech pathologist, or psychologist will frame it functionally. The participant, where they can, will frame it in their own terms. Each of these voices is real, and each of them matters for a well-rounded support plan.
For the narrower question of whether a medication constitutes regulated chemical restraint under the NDIS framework, however, only one voice carries determinative weight: the prescriber's documented clinical purpose. The other framings are context — useful, often vital context — but they are not classification evidence. The hierarchy is clear: the documented purpose recorded by the specialist prescriber (or, where no specialist is involved, the general practitioner) is the authoritative source. Everything else informs the plan; nothing else decides the classification.
This is, in its own way, freeing. A BSP is not being asked to adjudicate between competing accounts of why a medication is being given. The job is to establish what the prescriber documented, and — where that documentation is thin, ambiguous, or absent — to request clarification from the prescriber through legitimate channels rather than reconstructing a classification out of the surrounding voices.
For family members and guardians
When a Behaviour Support Practitioner reviews a psychotropic medication your relative has been prescribed, they are not second-guessing the prescriber's clinical decision. They are checking a separate question: whether, given the documented purpose recorded by the prescriber, the medication counts as a regulated restrictive practice under the NDIS framework — and, if so, whether the authorisation, behaviour support plan, and reduction strategy required by the framework are in place. The medication keeps doing what the prescriber prescribed it for; the BSP is making sure the surrounding paperwork and safeguards exist.
For prescribers
The BSP's role in this review is documentary and framework-facing, not prescriptive. The classification — is this medication a regulated restrictive practice? — rests on the purpose documented in your records. Where that purpose is clearly therapeutic, the framework typically does not apply. Where the documented purpose is to influence behaviour, or where the documentation is thin or silent on purpose, the BSP is obliged to surface the question and, where useful, to ask you to clarify what was intended.
The aim is to coordinate early rather than discover a classification mismatch at audit. The BSP is not authorised to alter a prescription, and any defence of ongoing use — if reduction has been attempted and reversed — is anchored in your clinical reasoning, not theirs.
Aged-care equivalent
The parallel restrictive-practices regime for aged-care providers — same reasoning structure, different statute and regulator.
The reasoning structure on every substance page is largely transferable to the parallel aged-care restrictive-practices framework administered by the Aged Care Quality and Safety Commission. The Commonwealth Aged Care Act governs in place of the NDIS Rules, and the regulator and authorisation pathway differ; the medication-context analysis is otherwise the same.